Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

State of the ART: Safety and Tolerability of HIV Treatments in Aging Patients
  • CME
  • CE

Credits Available
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Registered Nurses: 0.5 Nursing contact hours
Pharmacists: 0.5 contact hours (0.05 CEUs)
Released: September 7, 2022 Expiration: September 6, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare
Marta Boffito, MD, PhD, FRCP
Julian Falutz, MD, FRCPC

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Select optimal first-line HIV regimens for individual patients, integrating safety and tolerability considerations alongside other important factors
  • Apply appropriate ART modification strategies for patients experiencing adverse events or poor tolerability while receiving a virologically suppressive regimen
  • Incorporate patient characteristics into ART strategies to optimize HIV care for special populations

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Marta Boffito, MD, PhD, FRCP

Consultant Physician/Professor
HIV/Research
Chelsea and Westminster Hospital
Imperial College London
London, United Kingdom

Marta Boffito, MD, PhD, FRCP; consultant/advisor/speaker: Cipla, Gilead, GSK, Janssen, MSD, ViiV; research support: Novavax, Roche, Valneva.
Julian Falutz, MD, FRCPC

Associate Professor of Medicine
Department of Medicine
McGill University School of Medicine
Director
Comprehensive HIV and Aging Initiative
Chronic Viral Illness Service
McGill
Montreal, Quebec, Canada

Julian Falutz, MD, FRCPC; consultant/advisor/speaker: Gilead, Merck, ViiV.

Staff

Jacqueline Meredith, PharmD, BCIDP

Scientific Director

Jacqueline Meredith, PharmD, BCIDP, has no relevant financial relationships to disclose.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant financial relationships to disclose.
Zachary Schwartz, MSc

Scientific Director

Zac Schwartz, MSc, ELS, has no relevant financial relationships to disclose.
Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer Blanchette, PhD, has no relevant financial relationships to disclose.
Julie Skowronski, NP
Julie Skowronski, FNP-BC, has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare professionals who care for patients with HIV infection.

Goal

The goal of this activity is to improve learners’ competence in individualizing ART regimens for HIV by examining patient characteristics and the latest ART safety and tolerability data.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.50 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.50 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-220-H02-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.50 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 07, 2022, through September 06, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

State of the ART: Safety and Tolerability of HIV Treatments in Aging Patients
  • CME
  • CE

Loading...
Learn about ART safety in aging PWH and approaches to deprescribing ARV and non-ARV medications during this clinical conversation between experts.
Marta Boffito, MD, PhD, FRCP
Julian Falutz, MD, FRCPC
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Registered Nurses: 0.5 Nursing contact hours
Pharmacists: 0.5 contact hours (0.05 CEUs)
Released: September 7, 2022 Expiration: September 6, 2023

Related Content

Discussion of key considerations for switching antiretroviral therapy when the patient is pregnant, from Clinical Care Options (CCO)

person default Annette Haberl, MD William R. Short, MD, MPH, AAHIVS Released: November 23, 2022

Clinical Care Options (CCO) presents expert faculty discussing new data from AIDS 2022, from nursing perspectives

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
person default Allison Webel, PhD, RN Mitchell J. Wharton, PhD, RN, FNP-BC, CNS, ACRN
Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: November 22, 2022 Expired: November 21, 2023

Prof Don Smith discusses new HIV data from IDWeek 2022 on long-acting cabotegravir plus rilpivirine in this commentary from Clinical Care Options (CCO)

Don Smith, MD Released: November 22, 2022

Dr Milosz Parczewski discusses HIV Glasgow 2022 reports on the impact of the war in Ukraine on HIV care in Eastern Europe, from Clinical Care Options (CCO)

Milosz Parczewski, MD, PhD Released: November 22, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings